Abstract
Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials. Copyright © 2012 by the American Society of Nephrology.
Cite
CITATION STYLE
Waldman, M., & Austin, H. A. (2012, September 28). Treatment of idiopathic membranous nephropathy. Journal of the American Society of Nephrology. American Society of Nephrology. https://doi.org/10.1681/ASN.2012010058
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.